Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With MS Treated With Ampyra (Dalfampridine-ER): STUDY

Image Source: MI2G

Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-Ampyra (fampridine) treatment of patients with MS: STUDY

Image Source: HEALTH

Effect of Amprya (Fampridine-PR (prolonged released 4-aminopyridine)) on the manual functions of patients with MS: STUDY

Image Source: HEALTH

Effect of Ampyra (Fampridine-PR / prolonged released 4-aminopyridine) on the manual functions of patients with MS: STUDY

Image Source: DRUGS.COM

MS Patients Show Better Gait and Balance with Ampyra (Dalfampridine) Treatment

Withdrawal/reinitiation study expands on known walking speed benefits of approved MS therapy

In a new study, researchers evaluated the effect of dalfampridine treatment in people with multiple sclerosis (MS) and observed significant improvements in not only walking speed and distance, but also in gait and balance. The paper, titled “Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis,” was published in the International Journal of MS Care.

Safety profile of Ampyra (dalfampridine) extended release in MSs: 5-year postmarketing experience in the United States: STUDY

Image Source: HEALTH

Effects of Ampyra (dalfampridine) Extended-Release Tablets on 6-Minute Walk Distance in Patients With MS: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial: STUDY

Image Source: ALEXXBACIU

Effects of Ampyra (Dalfampridine) on Multi-Dimensional Aspects of Gait and Dexterity in Multiple Sclerosis among Timed Walk Responders and Non-Responders: STUDY

Image source: YOUTUBE

Relationship Between Timed 25-Foot Walk Impairment and Diffusion Tensor Imaging Markers in Multiple Sclerosis: STUDY

Image source: http://article.wn.com/

Long-term safety and efficacy of Ampyra (dalfampridine) for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials: STUDY

Ampyra (Dalfampridine) Effects Beyond Walking Speed in Multiple Sclerosis: Results from the STEADY Study: STUDY

Long-term safety and efficacy of Ampyra (dalfampridine) for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials: STUDY

Prescriber utilization of Ampyra (dalfampridine) extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis: STUDY